Table 1.
Baseline characteristics
| ORBIT-AF | GARFIELD-AF | |
|---|---|---|
| N | 22 760 | 52 032 |
| Age (years) | 73 (65–80) | 71 (63–78) |
| Male | 13 208 (58%) | 29 042 (56%) |
| Race | ||
| White | 19 903 (87%) | 32 005 (63%) |
| Black | 1127 (5%) | 243 (0.5%) |
| Hispanic | 1073 (5%) | 3392 (7%) |
| Other | 657 (3%) | 15 108 (30%) |
| Diabetes mellitus | 6294 (27%) | 11 546 (22%) |
| Hypertension | 18 474 (81%) | 39 610 (76%) |
| History of bleedinga | 1463 (6%) | 1416 (3%) |
| Cirrhosis | – | 294 (<1%) |
| COPD | 3065 (13%) | – |
| Cancer | 4857 (21%) | – |
| Liver disease | 470 (2%) | – |
| PVD | 2358 (10%) | 2859 (6%) |
| History of stroke | 2864 (13%) | 3878 (8%) |
| History of systemic embolism | – | 335 (<1%) |
| CAD | 6990 (31%) | 11 253 (22%) |
| History of stent placement | – | 3-550 (7%) |
| History of CABG | 2600 (11%) | 1625 (3%) |
| Cognitive impairment/dementia | 489 (2%) | 764 (2%) |
| Obstructive sleep apnoea | 4045 (18%) | 805 (2%) |
| Current smoker | 1478 (6%) | 4201 (11%) |
| Drug abuse | 270 (1%) | – |
| Alcohol abuseb | 861 (4%) | 1026 (2%) |
| AF type | ||
| New onset | 6708 (29%) | 23 331 (45%) |
| Paroxysmal | 9464 (42%) | 14 307 (28%) |
| Persistent | 3255 (14%) | 7758 (15%) |
| Permanent | 3333 (15%) | 6630 (13%) |
| Heart rate | 72 (63–81) | 84 (70–105) |
| Systolic BP | 126 (116–138) | 130 (120–145) |
| Diastolic BP | 74 (67–80) | 80 (70–88) |
| Haemoglobin | 13.6 (12.3–14.7) | – |
| BMI | 30 (26–24) | 27 (24-31) |
| Estimated GFR | 70.55 (56.15–86.29) | – |
| Chronic kidney diseasec | 6609 (31%) | 5355 (10%) |
| VKA | 8749 (38%) | 20 183 (39%) |
| DOAC | 10 214 (45%) | 14 123 (28%) |
| Antiplatelet (with or without OAC) | 9006 (40%) | 18 104 (35%) |
Values reported as median (interquartile range) or N (%) as appropriate.
AF, atrial fibrillation; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass graft; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DOAC, direct-acting oral anticoagulant; GFR, glomerular filtration rate; OAC, oral anticoagulant; PVD, peripheral vascular disease; VKA, vitamin K antagonist.
a
History of gastrointestinal bleeding only for ORBIT I and II.
b
Alcohol abuse is defined as heavy alcohol use in GARFIELD-AF.
c
Moderate to severe CKD only for GARFIELD-AF, any CKD for ORBIT-AF.